Feed HRMY
HR

Harmony Biosciences Holdings, Inc.

HRMY · NASDAQ

$42.02 -1.29% (-$0.55)
1M +10.14%
Market Cap $2.47B
P/E Ratio 13.65x
Div. Yield -
ROE 20.06%

Bulios Fair Price

$58.84

40.0% upside

Trenutna cena

$42.02

Podcenjeno Poštena vrednost Precenjeno

Po podatkih Bulios Fair Price je delnica HRMY trenutno podcenjena glede na svojo tržno ceno. Kako deluje?

Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?

Piotroski F-Score Moderate
5/9
Valuation
87 /100
Cheap
P/FCF 6.97x
P/E 13.65x
P/B 2.48x
Growth
74 /100
Growing
FCF growth 34.09%
EPS growth 3.01%
Book val. growth 29.27%
Profitability
99 /100
Strong
Op. margin 24.03%
Gross margin 75.42%
FCF margin 36.97%
Quality
83 /100
Excellent
ROA 13.20%
ROIC 14.96%
Asset turnover 0.70x
Debt
100 /100
Low
Int. coverage 18.62x
Debt/Equity 0.15x
Net debt/EBITDA -1.43x
Stability
90 /100
Stable
EPS volatility 24.29%
Beta 0.93x
Profitable years 5

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o HRMY
Online

O podjetju

Harmony Biosciences Holdings, Inc. (HRMY) is an American company specializing in research, development, and commercialization of drugs and therapies for sleep disorders and neurological conditions. With activities in biotechnology and pharmaceuticals, Harmony Biosciences Holdings is a key player in the world of sleep disorder and neurological condition treatment. Their research focuses on innovative treatment approaches and therapies for various sleep disorders, such as narcolepsy. The company aims to improve the lives of patients suffering from these conditions and provide modern treatment solutions. Harmony Biosciences Holdings is characterized by expertise in neurology and the treatment of sleep disorders. Harmony Biosciences Holdings, Inc. (HRMY) shares could be suitable for investors looking for an investment opportunity in the biotechnology and pharmaceutical sector with a company focused on innovations in the treatment of sleep disorders and neurological conditions and enhancing the quality of life for patients.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Biotechnology

CEO

Jeffrey Dayno

Employees

293

Headquarters

Plymouth Meeting

Prihajajoči dogodki

03 NOV.

Earnings

Upcoming earnings report

44d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.